Needham Reiterates Buy on Axsome Therapeutics, Maintains $130 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Ami Fadia has reiterated a Buy rating on Axsome Therapeutics (NASDAQ:AXSM) and maintained a price target of $130.
September 05, 2024 | 10:12 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Ami Fadia has reiterated a Buy rating on Axsome Therapeutics and maintained a price target of $130, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $130 price target by Needham suggests a positive outlook for Axsome Therapeutics. This could lead to increased investor confidence and potentially a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100